Clarity Pharma says its prostate cancer treatment has achieved ‘complete response’

ASX medtech Clarity Pharma has seen startling results from the dosing of a patient suffering a severe and often lethal form of prostate cancer.

Finally, some good news for prostate cancer patients. Picture: Getty Images

Clarity Pharma (ASX:CU6) jumped 7 per cent on Tuesday morning after revealing that the first prostate cancer patient t dosed with two cycles of its drug had achieved a complete response to treatment.

The patient had already failed multiple lines of treatment, including hormone therapy, an investigational agent and chemotherapy.

He was suffering metastatic castration-resistant prostate cancer – a disease that comes with a very grim prognosis.

The five-year survival rate for metastatic CPRC is around 30 per cent.

---

For the latest health news, sign up here for free Stockhead daily newsletters

---

The story was very different with 67Cu-SAR-bisPSMA at 8GBq, with the results meeting RECIST criteria (response evaluation criteria in solid tumours).

The patient received the first cycle of 67Cu-SAR-bisPSMA as part of Cohort 2 of Clarity’s theranostic SECuRE trial, which is evaluating the drug in patients with mCRPC (metastatic castration-resistant prostate cancer).

After that treatment, he showed a reduction of PSA (prostate-specific antigen) level of more than 99 per cent.

---

MORE FROM STOCKHEAD: Medtechs poised for glory | Aroa targets $US300m trauma market | Recce steps up anti-infection fight | Acne treatment breakthrough

---

The patient then received a second cycle of 67Cu-SAR-bisPSMA, which reduced his PSA to undetectable levels.

PSA is a well known marker of tumour burden and clinical response to treatment, as well as an indicator of the recurrence of prostate cancer.

A complete response (absence of detectable cancer after treatment) was observed in all but one lesion, assessed by computed tomography (CT).

That one lesion showed a reduction in size from 27mm to 12mm, missing the complete response cut-off by only 2mm based on RECIST assessment.

---

Visit Stockhead, where ASX small caps are big deals

---

Importantly, no PSMA uptake was observed in any of the lesions using 64Cu-SAR-bisPSMA following the second cycle of 67Cu-SAR-bisPSMA.

Clarity’s executive chairperson, Dr Alan Taylor, said he was very excited with this incredible response of the first patient to be dosed twice at what would be considered a therapeutic dose.

“We hope to replicate this remarkable result in many patients, and confirm the favourable safety profile of this agent,” Taylor said.

By 1pm, Clarity’s share price had eased from its morning highs, but was still up by more than 5 per cent for the day.

Now read: Radiopharmaceutical emerges as the hottest space in biotech; here’s what it means for Clarity Pharma

This content first appeared on stockhead.com.au

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox. Click here

Originally published as Clarity Pharma says its prostate cancer treatment has achieved ‘complete response’